Author

Vivian M. Liu

Observed name: Vivian M Liu

Institutions: University of Washington, Fred Hutch Cancer Center

Observed institutions: Harvard University, University of Washington, Fred Hutch Cancer Center, Harvard–MIT Division of Health Sciences and Technology, Dana-Farber Cancer Institute, Koch Institute for Integrative Cancer Research At MIT, Massachusetts Institute of Technology

ORCID: 0000-0002-9118-6204

Observed ORCID: 0000-0002-9118-6204

OpenAlex ID: A5075168046

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

2019 · Romain Guièze, Vivian M. Liu, et al. · Cancer Cell · 360

The Role of Pyruvate Kinase M2 in Cancer Metabolism

2015 · Vivian M. Liu, Matthew G. Vander Heiden · Brain Pathology · 48

Cancer‐associated mutations in human pyruvate kinase M2 impair enzyme activity

2019 · Vivian M. Liu, Andrea J. Howell, et al. · FEBS Letters · 26

MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers

2019 · Vivian M. Liu, Romain Guièze, et al. · Blood · 5

Genetic Determinants of Venetoclax Resistance in Lymphoid Malignancies

2018 · Romain Guieze, Vivian M Liu, et al. · Blood · 5

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

2024 · Vivian M. Liu, Megan Othus, et al. · Blood · 1

Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML.

2026 · Vivian M Liu, Megan Othus, et al. · PubMed

Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML

2026 · Vivian M. Liu, Megan Othus, et al. · Blood Neoplasia

Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report

2024 · Jasmine Naru, Megan Othus, et al. · eJHaem

Genomic Basis for Resistance to BCL-2 Inhibition in Hematologic Malignancies

2019 · Vivian M. Liu · Digital Access to Scholarship at Harvard (DASH) (Harvard University)

Works count: 10

Citation count: 445

H-index: 5

I10-index: 3